Read now


Discover the conference highlights

Meaningful outcome measures for migraine medications


  • “Decrease in migraine frequency” followed by “decrease in migraine severity” were the top priority outcomes for stakeholders in migraine medications; this understanding will help inform value-based contracts between patients and industry.

Why this matters

  • Migraine is a common neurological problem which causes significant disability.

  • Treatment options for migraine have expanded in the past few years, with the introduction of novel anti-migraine therapies including monoclonal antibodies; however, these novel agents are very expensive, and their real-world value is yet to be fully demonstrated.

  • Value-based contracts work by linking medication costs to predefined, real-world performance metrics to help ensure that incentives are aligned and risk is shared between payers and drug manufacturers; in this way, patient medication costs are limited by the measurable value they receive from their medication, with the additional costs covered by the manufacturers.

  • It is unclear which are the most meaningful outcome measures for stakeholders, including patients, employers, payers, providers, and industry, regarding migraine medications.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.